2019
DOI: 10.1016/j.hpb.2019.10.1521
|View full text |Cite
|
Sign up to set email alerts
|

Protection of acute renal injury in severe experimental acute pancreatitis

Abstract: Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a 5-year survival of 7.7%.[1] Treatment with cytotoxic agents extends life expectancy by a few months.[2] To improve this poor outcome new drug regimens against key features of PDAC's deadly behavior are urgently warranted. This study is the first to employ phosphotyrosine-based kinase screens on (pre)clinical PDAC models and tissues to understand the aggressive nature and identify new drug targets. Methods: We performed phosphoproteo… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles